Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.

Zhong J, Rao X, Rajagopalan S.

Atherosclerosis. 2013 Feb;226(2):305-14. doi: 10.1016/j.atherosclerosis.2012.09.012. Epub 2012 Sep 21. Review.

PMID:
23083681
2.

The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidence.

Pala L, Rotella CM.

J Diabetes Res. 2013;2013:590456. doi: 10.1155/2013/590456. Epub 2013 Jun 18. Review.

3.

DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.

Zhong J, Maiseyeu A, Davis SN, Rajagopalan S.

Circ Res. 2015 Apr 10;116(8):1491-504. doi: 10.1161/CIRCRESAHA.116.305665. Review.

4.

Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis.

Mulvihill EE, Varin EM, Gladanac B, Campbell JE, Ussher JR, Baggio LL, Yusta B, Ayala J, Burmeister MA, Matthews D, Bang KWA, Ayala JE, Drucker DJ.

Cell Metab. 2017 Jan 10;25(1):152-165. doi: 10.1016/j.cmet.2016.10.007. Epub 2016 Nov 10.

5.

Cardiovascular effects of incretins in diabetes.

Advani A, Bugyei-Twum A, Connelly KA.

Can J Diabetes. 2013 Oct;37(5):309-14. doi: 10.1016/j.jcjd.2013.06.010. Review.

PMID:
24500557
6.

Degradation of Incretins and Modulation of Blood Glucose Levels by Periodontopathic Bacterial Dipeptidyl Peptidase 4.

Ohara-Nemoto Y, Nakasato M, Shimoyama Y, Baba TT, Kobayakawa T, Ono T, Yaegashi T, Kimura S, Nemoto TK.

Infect Immun. 2017 Aug 18;85(9). pii: e00277-17. doi: 10.1128/IAI.00277-17. Print 2017 Sep.

7.

Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

Moore KB, Saudek CD.

Am J Ther. 2008 Sep-Oct;15(5):484-91. doi: 10.1097/MJT.0b013e3180ed42dc. Review.

PMID:
18806525
8.

Incretin effect: GLP-1, GIP, DPP4.

Kazafeos K.

Diabetes Res Clin Pract. 2011 Aug;93 Suppl 1:S32-6. doi: 10.1016/S0168-8227(11)70011-0. Review.

PMID:
21864749
9.

Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.

Klemann C, Wagner L, Stephan M, von Hörsten S.

Clin Exp Immunol. 2016 Jul;185(1):1-21. doi: 10.1111/cei.12781. Epub 2016 May 13. Review.

10.

Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.

Gong Q, Rajagopalan S, Zhong J.

Int J Cardiol. 2015 Oct 15;197:170-9. doi: 10.1016/j.ijcard.2015.06.076. Epub 2015 Jun 27. Review.

PMID:
26142202
11.

Incretin-based therapies and cardiovascular risk.

Mannucci E, Dicembrini I.

Curr Med Res Opin. 2012 May;28(5):715-21. doi: 10.1185/03007995.2012.678940. Epub 2012 Apr 13. Review.

PMID:
22439700
12.

Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.

Vergès B, Bonnard C, Renard E.

Diabetes Metab. 2011 Dec;37(6):477-88. doi: 10.1016/j.diabet.2011.07.001. Epub 2011 Aug 25. Review.

PMID:
21871831
13.

Incretin-based therapy of type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Holst JJ.

Curr Protein Pept Sci. 2009 Feb;10(1):46-55. Review.

PMID:
19275672
14.

Update on incretin hormones.

Phillips LK, Prins JB.

Ann N Y Acad Sci. 2011 Dec;1243:E55-74. doi: 10.1111/j.1749-6632.2012.06491.x. Review.

PMID:
22545749
15.

DPP4 inhibitors: a new approach in diabetes treatment.

Doupis J, Veves A.

Adv Ther. 2008 Jul;25(7):627-43. doi: 10.1007/s12325-008-0076-1. Review.

PMID:
18641927
16.

Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research.

Hocher B, Reichetzeder C, Alter ML.

Kidney Blood Press Res. 2012;36(1):65-84. doi: 10.1159/000339028. Epub 2012 Aug 27. Review.

17.

Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.

Mentlein R.

Best Pract Res Clin Endocrinol Metab. 2009 Aug;23(4):443-52. doi: 10.1016/j.beem.2009.03.005. Review.

PMID:
19748062
18.

Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors.

Chrysant SG, Chrysant GS.

Am J Cardiol. 2012 Jun 1;109(11):1681-5. doi: 10.1016/j.amjcard.2012.01.398. Epub 2012 Mar 16. Review.

PMID:
22425330
19.

Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection.

Avogaro A, de Kreutzenberg S, Fadini G.

Curr Pharm Des. 2014;20(14):2387-94. Review.

20.

Supplemental Content

Support Center